Lyell Immunopharma, Inc. (LYEL)
NASDAQ: LYEL · Real-Time Price · USD
14.86
-0.14 (-0.93%)
Nov 6, 2026, 4:00 PM EST - Market closed
Lyell Immunopharma Employees
Lyell Immunopharma had 161 employees as of December 31, 2025. The number of employees decreased by 139 or 46.33% compared to the previous year. That makes Lyell Immunopharma the 28,331st largest employer in the world and 3,569th in the United States.
Employees
161
Change (1Y)
-139
Growth (1Y)
-46.33%
Revenue / Employee
$93
Profits / Employee
-$1,584,845
Market Cap
365.34M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 161 | -139 | -46.33% | 161 | 0 |
| Dec 31, 2024 | 300 | 76 | 33.93% | 300 | 0 |
| Dec 31, 2023 | 224 | -50 | -18.25% | 224 | 0 |
| Dec 31, 2022 | 274 | 55 | 25.11% | 274 | 0 |
| Dec 31, 2021 | 219 | 29 | 15.26% | 219 | 0 |
| Mar 31, 2021 | 190 | - | - | 188 | 2 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| ProKidney | 231 |
| Allogene Therapeutics | 152 |
| MapLight Therapeutics | 133 |
| C4 Therapeutics | 104 |
| Prelude Therapeutics | 79 |
| AgomAb Therapeutics NV | 62 |
| TRex Bio | 60 |
| Atea Pharmaceuticals | 55 |
LYEL News
- 3 days ago - Lyell Immunopharma Transcript: Goldman Sachs’ RxChange Series: Framing Lyell’s next-generation lymphoma CAR-T data in 4Q - Transcripts
- 3 days ago - Lyell Immunopharma price target lowered to $35 from $36 at Stifel - TheFly
- 4 days ago - Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2026 - GlobeNewsWire
- 4 days ago - Why Is Lyell Immunopharma Stock (LYEL) Up over 43% Today? - TipRanks
- 4 days ago - Lyell Immunopharma to sell 7.43M shares at $10.77 in private placement - TheFly
- 4 days ago - Lyell Immunopharma Announces $80 Million Private Placement to Advance Ronde-Cel Toward Planned BLA Submission - GlobeNewsWire
- 4 days ago - Lyell Immunopharma to Present Positive Updated Ronde-Cel Data in More than 80 Patients at ASH 2026 from PiNACLE Pivotal Trial in 3L+ and from Phase 1/2 2L Cohort in Patients with Relapsed/Refractory Large B-Cell Lymphoma - GlobeNewsWire
- 4 days ago - Lyell Immunopharma Quarterly report: Q3 2026 - Filings